A retrospective cohort study showed that socioeconomic variables including race, marital status, insurance status, and geography are associated with rates of resection for early-stage pancreatic cancer. Most of these factors, however, were not associated with survival following resection.
A meta-analysis found that a number of dietary factors play a role in the risk of developing gastric cancer, with protective effects seen with fruit and certain vegetables and increased risk seen with high-salt foods and certain forms of alcohol.
This article reviews the current treatment paradigms for metastatic disease, focusing on ways to ameliorate symptoms and lengthen survival. We then summarize recent advances in our understanding of the molecular and cellular aspects of pancreatic cancer.
In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.
Blase Polite, MD, assistant professor of medicine at the University of Chicago and the track leader for the GI Colorectal Scientific Program Committee at ASCO, discusses the latest research in the field of colorectal cancer.